A Systematic Approach to Vildagliptin-Eudragit RL 100 Coated Nanoparticles by Combined Techniques of Solvent Evaporation and Nano-precipitation Using Quality by Design Concept
1, 1★★ Corresponding author
- 1Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, INDIA.
CORRESPONDENCE
Vinayak Shivamurthi Mastiholimath
Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, INDIA.
Received: 27-09-2023; Revised: 03-11-2023; Accepted: 01-12-2023.
Volume 14, Issue 1 · pp. 250-257 · 2023 · DOI: 10.5530/ijpi.14.1.31
ABSTRACT
Background: Diabetes is an endocrine disorder characterized by an abnormal increase in blood sugar level. Vildagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus.Purpose: The present work deals with the Quality by Design (QbD) approach based formulation and optimization of Vildagliptin-Eudragit RL 100 coated nanoparticles (VLD-EudNPs).Materials and Methods: VLD-Eud NPs were developed by combined technique of solvent evaporation and nano-precipitation. Optimization was done by 32 factorial designs. Prepared nanoformulations were characterized for percentage yield and morphology. Further in vitro drug release and kinetics were studied. The accelerated stability study of the optimized formulation was carried out for 3 months.Results: VLD-EudNPs ranged from 58.5±2.02 nm to 425.4±4.71 nm with a PDI of 0.27±0.036 to 0.52±0.086. Entrapment efficiency (% EE) of nanoformulations F1 to F9 ranged between 32.29±1.16 to 75.26±1.63%. The particles were found to be cylindrical-shaped, with a percentage yield of 54.7±3.45 to 84.4±1.51%. During the in vitro drug release study, at acidic pH, 68% of the drug following zero order kinetics. The optimized formulation has proven its stability during stability study.Conclusion: The present work concludes that prepared and optimized VLD-Eud NPs could be a better approach for sustained delivery of Vildagliptin for the management of diabetes mellitus as compared to traditional drug delivery.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Ammanage, A. S., & Mastiholimath, V. S. (2023). A Systematic Approach to Vildagliptin-Eudragit RL 100 Coated Nanoparticles by Combined Techniques of Solvent Evaporation and Nano-precipitation Using Quality by Design Concept. International Journal of Pharmaceutical Investigation, 14(1), 250-257. https://doi.org/10.5530/ijpi.14.1.31
Copyright and licence
© 2023 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0